AGA Clinical Practice Update: Coagulation in Cirrhosis

Area of Science:

• Hepatology
• Hematology
• Clinical Practice Guidelines

Background:

• Cirrhosis significantly alters coagulation pathways, presenting complex management challenges.
• Current understanding of hemostasis in cirrhosis is evolving, necessitating updated clinical guidance.

Purpose of the Study:

• To evaluate current data on altered coagulation mechanisms in cirrhosis.
• To provide guidance on interpreting coagulation tests in liver disease.
• To assist practitioners in appropriate use of anticoagulation and pro-coagulants in cirrhosis.

Main Methods:

• Expert review based on impactful publications in coagulation and cirrhosis.
• Development of best practice advice points agreed upon by all authors.
• Evaluation of current diagnostic and therapeutic strategies for coagulation abnormalities in cirrhosis.

Main Results:

• Global clot formation tests lack validated target levels for cirrhosis.
• Routine correction of coagulopathy is not recommended for low-risk procedures.
• Specific transfusion thresholds (hematocrit ≥25%, platelets >50,000, fibrinogen >120 mg/dL) are suggested for active bleeding or high-risk procedures.
• Thrombopoietin agonists are an alternative to platelet transfusions.
• 4-factor prothrombin complex concentrate and anti-fibrinolytic therapy have potential roles.
• Heparin and direct-acting anticoagulants show promise for venous thrombosis but require further study in advanced liver disease.

Conclusions:

• Judicious use of blood products and targeted interventions is crucial in managing coagulation in cirrhosis.
• Further research is needed to validate new diagnostic tools and refine anticoagulant strategies in liver disease.
• Clinical practice should adapt to evolving evidence, prioritizing patient safety and optimizing hemostatic balance.